Close Menu

Mass General

Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management. 

Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.

The trial will use Natera's Signatera test to determine patient enrollment eligibility based on the presence of ctDNA and to evaluate response based on ctDNA clearance.

In a preliminary study, the group reported high accuracy for the detection of breast cancer within an hour by combining a fluorescence flow cytometer with fine-needle biopsies.

Developed by the Ragon Institute, the ELISA-based test measures antibodies that bind to the receptor binding domain of the SARS-CoV-2 spike protein.

Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.

The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals. 

The three hospital laboratories' tests are all real-time PCR assays for detecting the virus from nasopharyngeal swabs and bronchoalveolar lavage.

CareDx will use NanoString's new Human Organ Transplant panel to develop HistoMap, a gene expression profiling test to identify allograft rejection.

The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.

Pages